⌘K

Home/Filings/4/A/0000905718-22-000429

4/A//SEC Filing

Gudin Jeffrey 4/A

Accession 0000905718-22-000429

CIK 0001708331other

View on SEC.gov Company Profile

Filed

Feb 24, 7:00 PM ET

Accepted

Feb 25, 4:47 PM ET

Size

5.4 KB

Accession

0000905718-22-000429

Insider Transaction Report

Form 4/AAmended

Period: 2022-01-31

Virpax Pharmaceuticals, Inc.VRPX

DirectorChief Medical Officer

Transactions

Award
Stock Option (right to buy)
2022-01-31+60,676→ 60,676 total
Exercise: $2.13Exp: 2032-01-31→ Common Stock (60,676 underlying)

Footnotes (1)

[F1]The option vests in three equal annual installments commencing on January 31, 2023.

Documents

1 file

4
virpax_fm4ajan312022.xml

Issuer

Virpax Pharmaceuticals, Inc.

CIK 0001708331

Entity typeother

Related Parties

1

filerCIK 0001818449

Filing Metadata

Form type: 4/A
Filed: Feb 24, 7:00 PM ET
Accepted: Feb 25, 4:47 PM ET
Size: 5.4 KB

View on SEC.gov